# An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

> **NCT05102409** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Reproxalap Ophthalmic Solution (0.25%)
- **DRUG:** Xiidra® (5% lifitegrast ophthalmic solution)

## Key facts

- **NCT ID:** NCT05102409
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2021-10-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102409, "An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05102409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*